Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

Overview of attention for article published in BMC Medicine, March 2013

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 27 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 23 publications that cite this research output.

23

The most recent citing publications are shown below. View all 23 publications that cite this research output on Dimensions.

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer

Article in The Oncologist (May 2023)

Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications

Article in Cells (July 2022)

Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Article in BMC Cancer (June 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.